Evidence map›Paper›PMID 34488831›Full record

ArticleItalian journal of pediatrics2021

Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children.

Luisa Santangelo, Giuseppe Stefano Netti, Diletta Domenica Torres, Giovanni Piscopo, Vincenza Carbone, Luciana Losito, Leonardo Milella, Maria Luigia Lasorella, Pasquale Conti, Delio Gagliardi and 6 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Italian journal of pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Luisa Santangelo *Pediatric Nephrology and Dialysis Unit, Pediatric Hospital 'Giovanni XXIII', Bari, Italy.
Giuseppe Stefano Netti *Department of Medical and Surgical Sciences, Clinical Pathology Unit and Center for Molecular Medicine, University of Foggia, Viale Luigi Pinto -, 71122, Foggia, Italy. giuseppestefano.netti@unifg.it.ORCID http://orcid.org/0000-0003-3495-2707
Diletta Domenica TorresPediatric Nephrology and Dialysis Unit, Pediatric Hospital 'Giovanni XXIII', Bari, Italy.
Giovanni PiscopoPediatric Nephrology and Dialysis Unit, Pediatric Hospital 'Giovanni XXIII', Bari, Italy.
Vincenza CarbonePediatric Nephrology and Dialysis Unit, Pediatric Hospital 'Giovanni XXIII', Bari, Italy.
Luciana LositoScientific Institute I.R.C.C.S. "E. Medea"- Unit for Severe disabilities in developmental age and young adults (Developmental Neurology and Neurorehabilitation), Brindisi, Italy.
Leonardo MilellaIntensive Care Unit, Pediatric Hospital "Giovanni XXIII", Bari, Italy.
Maria Luigia LasorellaIntensive Care Unit, Pediatric Hospital "Giovanni XXIII", Bari, Italy.
Pasquale ContiPediatric Neurology Unit, Pediatric Hospital "Giovanni XXIII", Bari, Italy.
Delio GagliardiPediatric Neurology Unit, Pediatric Hospital "Giovanni XXIII", Bari, Italy.
Maria ChironnaDepartment of Biomedical Sciences and Human Oncology, Hygiene Unit, University of Bari "Aldo Moro", Bari, Italy.
Federica SpadaccinoDepartment of Medical and Surgical Sciences, Clinical Pathology Unit and Center for Molecular Medicine, University of Foggia, Viale Luigi Pinto -, 71122, Foggia, Italy.
Elena BresinClinical Research Center for Rare Diseases 'Aldo e Cele Daccò', Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Antonio TrabaccaScientific Institute I.R.C.C.S. "E. Medea"- Unit for Severe disabilities in developmental age and young adults (Developmental Neurology and Neurorehabilitation), Brindisi, Italy.
Elena Ranieri *Department of Medical and Surgical Sciences, Clinical Pathology Unit and Center for Molecular Medicine, University of Foggia, Viale Luigi Pinto -, 71122, Foggia, Italy.
Mario Giordano *Pediatric Nephrology and Dialysis Unit, Pediatric Hospital 'Giovanni XXIII', Bari, Italy.
Ospedale Pediatrico Giovanni XXIII · ITUniversity of Foggia · ITIRCCS Eugenio Medea · ITMario Negri Institute for Pharmacological Research · ITUniversity of Bari Aldo Moro · IT

Funding

University of Foggia University Research Projects 2019 (PRA 2019)
6 · The paper itself

Abstract

backgroundThe Neurological involvement is the most common extra-renal complication of Shiga toxin-producing E. coli-hemolytic uremic syndrome (HUS) or typical HUS. On brain magnetic resonance examination, main neurological signs encompass acute lesions of the basal ganglia and the white matter, which could usually regress after Eculizumab infusion. In contrast, peripheral nervous system (PNS) manifestations in typical HUS are very rare and, when occurring, they require a careful management of neurological sequelae and an intensive multidisciplinary neuro-rehabilitation program. CASE PRESENTATION: Here, we present two pediatric cases of severe and complicated typical HUS with PNS manifestations who required therapeutic treatment and an intensive multidisciplinary neuro-rehabilitation program. In both cases, PNS manifestations were followed by the recovery from typical HUS-related severe central neurological damage and manifested mainly with marked bilateral motor deficit and hyporeflexia/areflexia in the lower limbs. The peripheral polyneuropathy was treated with immunosuppressive therapy (methylprednisolone boluses, i.v. immunoglobulins, plasma exchange), followed by a prolonged intensive neuro-rehabilitation program. After 8 months of rehabilitation, both patients gained complete functional recovery.

conclusionsPNS manifestations during typical HUS are a rare event and potentially leading to severe disability. A timely clinical assessment is mandatory to set up a prompt therapeutic and rehabilitation program and to obtain a complete clinical and functional recovery.

Indexed as

Shiga-Toxigenic Escherichia coliAnti-Inflammatory AgentsChildChild, PreschoolEscherichia coli InfectionsFemaleHemolytic-Uremic SyndromeHumansImmunoglobulins, IntravenousMethylprednisoloneNeurological RehabilitationPlasma ExchangePolyneuropathiesAnti-Inflammatory AgentsImmunoglobulins, IntravenousMethylprednisoloneEculizumabEnterohemorrhagic Escherichia ColiHemolytic uremic syndromeNeurorehabilitationPeripheral nervous systemPlasma exchange

Identifiers

PMID34488831
PMCPMC8422760
OpenAlexW3196969827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.